P ertussis, also known as whooping cough, is a highly contagious disease caused by Bordetella pertussis (B. pertussis). It usually starts as a mild upper respiratory tract infection that within a few days turns into attacks of a dry, chocking cough. Despite the fact that populations living in industrialized countries are highly immunized against pertussis, the incidence of the disease has recently increased mainly among adolescents and young adults. 1 Reemergence of pertussis raises concerns whether current vaccination strategies are sufficiently effective. It is well documented that immunity induced by pertussis vaccine wanes over time unless a booster dose is administered. 2, 3 As a result, young people may be prone to contracting the disease. For these reasons, many countries considered the introduction of an additional single dose of pertussis vaccine between 11 and 18 years of age. In Poland, similar to other European countries and the United States, the immunization schedule against pertussis includes the administration of 5 doses of pertussis vaccine up to 6 years of age. 4, 5 For adults, a booster dose of pertussis vaccine is recommended every 10 years. 5, 6 It seems that patients with inflammatory bowel disease (IBD) might be at a higher risk of many infections because of the disease itself and mainly in relation to immunosuppressive treatment. 7, 8 They also have a higher risk of severe clinical courses of all infections. 9 Moreover, these patients could have lowered response to vaccinations as previously reported. [10] [11] [12] All these factors taken together prompted that the Crohn's and Colitis Foundation of America and the European Crohn's and Colitis Organization recommend maximal adherence to immunization schedule and emphasize the necessity of evaluation of the postvaccination immune response in patients with IBD. 13, 14 The aim of this study was to assess the immunogenicity of a booster dose of acellular pertussis vaccine in pediatric patients with IBD and to compare their response with healthy controls.
MATERIALS AND METHODS

Study Design
We conducted this open, multicenter, prospective study in 6 pediatric university hospitals in Poland (cities of Warsaw, Poznan, Wroclaw, Lodz, and Katowice) between July 2013 and April 2015.
Patients and Controls
We investigated children and adolescents with IBD between 11 and 18 years of age. Diagnosis of Crohn's disease (CD) and ulcerative colitis (UC) was based on established revised Porto criteria that included results of endoscopic, histological, and radiological examinations. 15 We used Pediatric Crohn's Disease Activity Index and the Pediatric Ulcerative Colitis Activity Index to assess the severity of CD and UC, respectively. 16, 17 Any patient with CD with a Pediatric Crohn's Disease Activity Index score #10 and any patient with UC with Pediatric Ulcerative Colitis Activity Index score ,10 was considered to be in remission. Study participants belonged to 1 of the 4 groups. Group 1 consisted of patients with IBD who were not treated with immunosuppressive agents. Group 2 included patients who were on thiopurine treatment with azathioprine 2.5 to 3 mg$kg 21 $d 21 or 6-mercaptopurine 1.5 mg$kg 21 $d 21 for $12 weeks. Group 3 included patients treated with both thiopurines and infliximab or adalimumab. Group 4 consisted of healthy subjects who had no chronic disease and were on no immunosuppressive therapy. All study participants were immunized against pertussis according to the following immunization schedule: 3 doses of vaccine in the first year of life, 1 dose of vaccine in the second year of life, and 1 booster dose at the age of 6 years; they have not got any pertussis vaccination after the age of 6 years, and had no documented pertussis infection.
Boostrix
Tetanus, diphtheria, and acellular pertussis vaccine from GlaxoSmithKline Biologicals (Rixensart, Belgium) was used. Each 0.5-mL dose of the vaccine contains 5 Lf of tetanus toxoid, 2.5 Lf of diphtheria toxoid, 8 mg of inactivated pertussis toxoid (PT), 8 mg of formaldehyde-treated filamentous hemagglutinin (FHA), and 2.5 mg of pertactin (69 KD outer membrane protein). Each 0.5-mL dose contains aluminum hydroxide as adjuvant (no more than 0.39 mg aluminum by assay), 4.4 mg of sodium chloride, #100 mg of residual formaldehyde, and #100 mg of polysorbate 80 (Tween 80). 18 Boostrix was administered intramuscularly in the deltoid muscle. Vaccines were stored at temperature between 28C and 58C.
Intervention
At the initial visit, demographic data, medical history including pertussis or parapertussis infections, and physical examination data were obtained. Medical records of study participants were reviewed paying special attention to previous exposure to pertussis vaccines. Pediatric Crohn's Disease Activity Index and Pediatric Ulcerative Colitis Activity Index were used to assess a disease activity in patients with CD and UC, respectively. All the included subjects were given 1 dose of Boostrix. Serum samples were collected at 2 time points: before vaccination and 6 to 8 weeks after vaccination. Sera were kept frozen at 2208C to 2708C until tested. Sera were tested for the qualitative and semiquantitative detection of immunoglobulin G (IgG) antibodies against PT and FHA by a standardized enzyme-linked immunoassay Bordetella pertussis IgG/IgA enzyme-linked immunoassay-VIROTECH; Genzyme Virotech GmBH, Rüsselsheim, Germany.
Patients and controls were observed at least 30 minutes after vaccination in case of any immediate reaction occurrence. All patients were asked to note the presence of any local of systemic adverse effects for 3 days after the vaccination.
Outcomes
An adequate vaccine response, defined as postvaccinationspecific IgG antibody concentration .11 Virotech units, was determined as the primary outcome. The secondary outcomes were geometric median concentrations (GMCs) and the rate of local and systemic adverse events. We also evaluated whether rate of adequate vaccine response is associated with immunosuppressive therapy.
Sample Size
Calculation of sample size was based on the results of 3 previous studies assessing the immune response to the pneumococcal vaccine, 11, 19, 20 which reported approximately 83% vaccine response rate in patients with IBD on aminosalicylates only and approximately 51% in patients with IBD on immunosuppressive therapy. To detect a difference of 32% between patients receiving aminosalicylates only and patients receiving immunosuppressive agents, with an alpha value of 0.05 and a power of 80%, 33 children were required in each group. Accounting for an expected dropout rate of 20%, we aimed to recruit 40 children per group.
Statistical Analysis
Data analysis was conducted using Statistica 12 (Statsoft Inc., Tulsa, OK) software. The Wilcoxon rank sum and Kruskal-Wallis tests were used to compare differences in selected variables. A Chi-squared test was used to compare differences in proportions. P values ,0.05 were considered statistically significant.
Ethical Consideration
The study was approved on August 21, 2012, by the Ethics Committee of the Medical University of Warsaw, Poland. All the parents and children $16 years were requested to give their consent before enrollment.
RESULTS
Demographics Data
In total, 138 subjects were enrolled in this study, including 109 patients with IBD and 29 healthy controls. There were 67 patients with CD and 42 patients with UC. The median age was similar within patients with IBD; they were older than healthy controls (P ¼ 0.0001). Disease severity was similar in patients in groups 1, 2, and 3. Baseline characteristics of the study population are summarized in Table 1 .
Adequate Vaccine Response and GMC
Adequate vaccine response rates in 4 study groups were as follows: group 1 88%, group 2 91%, group 3 90%, and group 4 72%, as shown in Figure 1 . We found no statistically significant differences in the rate of adequate vaccine response among the 4 study groups (P ¼ 0.11). No differences were observed between patients with IBD treated and not treated with immunosuppressive drugs (90.6% versus 88.2%, P ¼ 0.37). Adequate vaccine response rate was statistically significantly lower in patients with remission compared with those with mild disease (P ¼ 0.024), but there was no difference in vaccine response rates between patients with disease activity assessed as mild and moderate (P ¼ 0.5627).
GMCs for the study groups are shown in Table 2 . There were no flare-ups during the study period.
Adverse Effects
We did not note any serious adverse events after vaccination with booster pertussis vaccine. The most frequently reported local side effects included: tenderness in 12.3% (11/89) of the patients and 10.3% (3/29) of the controls, P ¼ 0.36; and soreness in 7.8% (7/89) of the patients and 10.3% (3/29) of the controls, P ¼ 0.11. Systemic side effects attributable to booster pertussis vaccine did not occur in this study. In patients with IBD, frequency and type of adverse events were not dependent on the type of therapy; P ¼ not significant for the 3 IBD groups. 
DISCUSSION
The results of our prospective study demonstrate that serologic response to booster pertussis vaccine was very high and irrespective of therapy type in IBD children and adolescents. For the first time, immunogenicity of pertussis vaccine was assessed in pediatric patients with IBD.
Our results are in line with the results of the only study assessing the immunogenicity of pertussis vaccine in adults with IBD. 21 Dezfoli et al found that the booster pertussis vaccine was immunogenic with a response rate for PT between 45% and 72% and for FHA between 64% and 86%. Our response rates were as high as 88% to 91%. Similar to Dezfoli et al, we did not find statistically significant differences between response rates in patients with IBD and healthy controls. We cannot simply compare the results of these 2 studies directly because we used different laboratory methods. Dezfoli et al assessed antibodies against PT and FHA separately. We decided to use the serological test that evaluates the 2 B. pertussis antigens jointly. Despite this difference, in both studies, the booster dose of pertussis vaccine was immunogenic; however, it seems that immunogenicity of the vaccine is higher in children than in adults. It is probably because in both studies, booster vaccination against pertussis was not performed after the age of 7. In our study, the mean age of study participants was 14 years compared with approximately 40 years in the Dezfoli et al study; therefore, in their study, "the time of antibody weaning" was much longer. It is well established that protection against pertussis is relatively short term and wanes; hence, booster doses are needed. Recently, it was proposed that an additional booster dose of the pertussis vaccine be added for healthy adolescents, as has already been performed in many European countries such as Belgium, Czech Republic, Finland, France, and Norway, and in the United States. 22, 23 The results of our study confirmed the rationality of that proposal for adolescents or young adults with IBD. Moreover, the higher response rates in children and adolescents compared with people in their 40s may argue for immunization of patients with IBD with a booster dose of pertussis vaccine no later than in young adulthood. However, the proper time of booster vaccination against pertussis among patients with IBD needs further research.
We did not find any influence of thiopurines or anti-TNF alpha (P ¼ 0.11) on the booster pertussis response rate. Similar results were obtained by Dezfoli et al in their study among adults with IBD. In most studies assessing immunogenicity of inactivated vaccine given together with immunosuppressive treatment, especially anti-TNF alpha agents, lowered response rates were observed, 11, 19, 20 whereas in some studies, it was not. [24] [25] [26] Several factors could explain our findings. First, it could be suspected that the pertussis vaccine is so immunogenic that it may have stimulatory effect even in patients with a weakened immunologic response. Second, all patients in both our study and the Dezfoli et al study had previously been immunized against pertussis several years before they started treatment with immunosuppressive drugs. Their immunologic system was then primed and was essentially ready to generate antibodies against pertussis. Third, for pertussis being a common disease, we can expect that many of our patients were exposed to the B. pertussis (without presentation of disease symptoms), rendering their immune system ready to react. Finally, the fact that we do not know all the factors that could influence this response may explain the good postvaccination response rate we observed. As an example, Gisbert et al, 24 in their study, assessing the efficacy of hepatitis B vaccination in patients with IBD, found in the multivariate analysis that the age of the patients was the most important factor affecting response rate, not the treatment with immunosuppressive drugs. Dotan et al, 26 in their study, assessed the influence of thiopurines on cellular and humoral immune responses in patients with IBD. Patients with IBD were immunized against diphtheria and tetanus before introducing thiopurines and against Haemophilus influenzae type b after that. Before initiating thiopurine therapy and at 24 weeks, when the effect of therapy would be achieved, lymphocyte counts and their phenotypes and total quantitative immunoglobulin and IgG subclass levels were measured. The authors found no significant suppressive effects of thiopurines, at the doses used for treating IBD, on the systemic immune response. They concluded that thiopurines are immunomodulators rather than immunosuppressors. In our study, postvaccination GMCs increased between 2-fold and 4-fold among all 4 groups with no differences between study groups (Fig. 2) . In the Dezfoli et al study, a similar increase of postvaccination geometric mean titers was observed; however, the difference between prevaccination and postvaccination geometric mean titers was significantly lower among patients on combined biological and thiopurine therapy compared with healthy controls. Because of different laboratory tests used, we cannot compare those results with the results we obtained.
Boostrix seems to be a very safe vaccine. In this study, only local adverse events were reported; tenderness and soreness were the most common. Our results are in line with data from other studies, both in children 10, 12, 27 and adults with IBD. 11, [19] [20] [21] We did not note any flare-ups of IBD after the immunization. Data are limited, but vaccine administration does not seem to be a risk factor for the exacerbation of IBD. 10, 20, 26, 28, 29 It is important to emphasize that the examined inactivated vaccines seemed to be safe in all previously published studies both in children and in adults with IBD.
The results of our study demonstrate that booster pertussis vaccine can be considered highly immunogenic and safe for pediatric patients with IBD. The optimal time for immunization should be established through further studies. A shortcoming of this study is the lack of data on the duration of immunosuppressive treatment. We speculate that no differences in vaccine response rates between patients with or without immunosuppression and healthy controls could be explained by a short duration of treatment; however, more studies are needed to confirm this.
In conclusion, the results of our study demonstrate that a booster pertussis vaccine was highly immunogenic and safe in children and adolescents with IBD irrespective of treatment type.
